About NavDx®

What is the NavDx Test?

The NavDx test is the first and most clinically validated blood test that can detect HPV+ head & neck and anal cancer, often months before it shows up in clinical exams or on imaging. With a simple, non-invasive blood draw, NavDx can help your Provider uncover important information about your cancer status throughout your care journey, from before treatment begins through long-term monitoring after treatment ends.

Insurance Coverage

NavDx testing is covered by a growing number of commercial insurance companies. Coverage depends on the health insurance company and plan type. NavDx testing is covered by Medicare for surveillance of recurrence in patients with a documented history of HPV+ oropharyngeal or anal squamous cell carcinoma. For more information, visit naveris.com/insurance-billing.

Learn More About NavDx

Survivor Stories

Patient Education

Add Us to Your Contacts

CareDx®

Naveris Inc. (now part of CareDx), 21 Hickory Drive, Suite 600, Waltham, MA 02451
833-628-3747 | support@naveris.com | www.naveris.com
© 2026 Naveris, Inc. | US Patents 11,168,373 and 11,254,989 | NavDx-1026-275R2

1. Chera BS, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 2020. http://doi.org/10.1200/JCO.19.02444. 2. Kabarriti R, Lloyd S, Jabalee J, et al. Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers. 2025. https://doi.org/10.3390/cancers17020174. 3. Berger BM, Hanna GJ, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res. 2022. http://doi.org/10.1158/1078-0432.CCR-22-0562. 4. Upadhyay L, Hartzell M, Parikh AR, Strickland MR, Klempner S, and Malla M. Recent advances in the management of anal cancer. Healthcare. 2023. https://doi.org/10.3390/healthcare11233010. 5. Qian JY, Chen L, Wong W, et al. The Role of Circulating Tumor DNA (ctDNA) in the Treatment of Human Papilloma Virus-positive (HPV+) Oropharyngeal Squamous Cell Carcinoma. Cancer J. 2025. http://www.doi.org/10.1097/PPO.0000000000000769. 6. Masroor F, Corpman D, Carpenter DM, et al. Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2019. http://www.doi:10.1001/jamaoto.2019.1934. 7. Data on File, Naveris, Inc.

Patient Brochure

NavDx®
Optimizing HPV+ Cancer Care

know with confidence

NavDx is the most clinically validated blood test for monitoring HPV+ cancer





HPV+ cancer detection with a simple blood draw

The NavDx® test is the first and most clinically validated blood test that can detect HPV+ head & neck and anal cancer. With a simple, non-invasive blood draw, your provider can uncover critical information about your cancer across the care continuum.

NavDx®
Optimizing HPV+ Cancer Care

know more. worry less.

Fear of recurrence is often a significant worry after treatment. Even after successful therapy, studies show that up to 25% of head & neck cancer patients[3] and up to 30% of anal cancer patients[4] may experience recurrence.

The standard methods available to medical providers for recurrence monitoring have critical limitations that reduce their effectiveness. And, in fact, recurrences are rarely found through routine physical exam. Most are identified on imaging prompted by patient-reported symptoms.[5,6]

With the NavDx® test, you don't have to wait for symptoms to appear. Unlike physical exams, scopes, or imaging, NavDx looks for evidence of HPV+ cancer in your blood, so it helps detect recurrence wherever it is in your body. **And, it's backed by strong clinical evidence and over 120,000+ tests performed on nearly 40,000 patients.**[7]

Getting started with the NavDx test is easy.

Start the conversation with your provider.

Learn more about NavDx and your specific cancer type at naveris.com/patient or use the QR codes on the back of this brochure.

When Is NavDx® Used?

What Can It Tell Us?

Post-Treatment Monitoring (Surveillance)

- A negative result is a high-confidence indicator that no HPV+ cancer activity was detected at the time of testing
- A positive result prompts your provider that additional evaluation may be needed

Treatment

- NavDx can help monitor how your cancer is responding to treatment
- NavDx can help determine if any cancer remains following treatment

Pre-Treatment*

- Your provider may use NavDx to help confirm that your cancer is caused by HPV
- NavDx can help identify which strain of HPV caused your cancer

** NavDx detects HPV 16, 18, 31, 33, and 35.*

Benefits for Patients



Earlier Detection

Clinical studies show that regular NavDx® testing can reliably identify when cancer returns. In studies, head & neck cancer recurrence was detected a **median of 4 months earlier**[1] and anal cancer recurrence was detected a **median of 2 months earlier**[2] than with standard exams or imaging. If recurrence occurs, your provider can intervene sooner, when the chance for cure is greatest, treatment options can be optimized, and long-term side effects may be minimized.



Greater Assurance & Peace of Mind

The NavDx test's high accuracy, reliability, and superior performance mean a negative result offers strong reassurance that you are free of detectable disease ***at the time of testing***. You can live your life with greater peace of mind, higher confidence in your health status, and less fear of recurrence.



Access & Convenience

NavDx is easily accessible everywhere blood can be drawn in the US. The test is non-invasive, and no preparation is required. Your blood draw can be done in your provider's facility, or the NavDx Patient Navigation team can arrange for it to be completed somewhere more convenient for you, like a walk-in clinic or at home using a mobile lab service.